0001140361-17-033562.txt : 20170829
0001140361-17-033562.hdr.sgml : 20170829
20170829170023
ACCESSION NUMBER: 0001140361-17-033562
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170825
FILED AS OF DATE: 20170829
DATE AS OF CHANGE: 20170829
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sanofi
CENTRAL INDEX KEY: 0001121404
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
STATE OF INCORPORATION: I0
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19034
FILM NUMBER: 171058580
BUSINESS ADDRESS:
STREET 1: 54 RUE LA BOETIE
CITY: PARIS
STATE: I0
ZIP: 75008
BUSINESS PHONE: 33153774400
MAIL ADDRESS:
STREET 1: 54 RUE LA BOETIE
CITY: PARIS
STATE: I0
ZIP: 75008
FORMER NAME:
FORMER CONFORMED NAME: SANOFI-AVENTIS
DATE OF NAME CHANGE: 20040826
FORMER NAME:
FORMER CONFORMED NAME: SANOFI SYNTHELABO SA
DATE OF NAME CHANGE: 20010104
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000872589
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 133444607
STATE OF INCORPORATION: NY
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 777 OLD SAW MILL RIVER ROAD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
BUSINESS PHONE: 9143477000
MAIL ADDRESS:
STREET 1: 777 OLD SAW MILL RIVER ROAD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
4
1
form4.xml
FORM 4
X0306
4
2017-08-25
0000872589
REGENERON PHARMACEUTICALS INC
REGN
0001121404
Sanofi
54 RUE LA BOETIE
PARIS
I0
75008
FRANCE
true
Common Stock
2017-08-25
4
P
0
3684
479.1912
A
23811843
I
See note
Common Stock
2017-08-25
4
P
0
28586
479.9313
A
23840429
I
See note
Common Stock
2017-08-25
4
P
0
21360
480.7489
A
23861789
I
See note
Common Stock
2017-08-25
4
P
0
1302
481.6284
A
23863091
I
See note
Common Stock
2017-08-25
4
P
0
4485
482.8734
A
23867576
I
See note
Common Stock
2017-08-25
4
P
0
2000
484.21
A
23869576
I
See note
Common Stock
2017-08-25
4
P
0
5723
485.2798
A
23875299
I
See note
Common Stock
2017-08-25
4
P
0
2681
485.9939
A
23877980
I
See note
Common Stock
2017-08-25
4
P
0
2557
487.0108
A
23880537
I
See note
The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.
Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN").
Purchase prices range from $478.42 to $479.39 per share, inclusive.
Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventisub LLC ("Aventis"), formerly known as Aventis Pharmaceuticals Inc., an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 21,080,985 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors.
Purchase prices range from $479.43 to $480.39 per share, inclusive.
Purchase prices range from $480.44 to $481.32 per share, inclusive.
Purchase prices range from $481.47 to $482.09 per share, inclusive.
Purchase prices range from $482.49 to $483.45 per share, inclusive.
Purchase prices range from $483.70 to $484.63 per share, inclusive.
Purchase prices range from $484.86 to $485.85 per share, inclusive.
Purchase prices range from $485.86 to $486.79 per share, inclusive.
Purchase prices range from $486.92 to $487.57 per share, inclusive.
Exhibit 24 - Power of Attorney (incorporated herein by reference to Exhibit 24 to Form 4 filed by the Reporting Person with the SEC on February 3, 2016, with respect to Alnylam Pharmaceuticals, Inc.).
/s/ Alexandra Roger Attorney-in-fact
2017-08-29